Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Emi, Kamiyama"'
Autor:
Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki, Ichinosuke Hyodo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance anti
Externí odkaz:
https://doaj.org/article/e6e7417efabc4c09a8c6af99cb58e3cb
Autor:
Akihiko Shimomura, Toshimi Takano, Shunji Takahashi, Yasuaki Sagara, Junichiro Watanabe, Eriko Tokunaga, Tetsu Shinkai, Takahiro Kamio, Kunika Kikumori, Emi Kamiyama, Yoshihiko Fujisaki, Dan Saotome, Toshinari Yamashita
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:160-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5a27284cedf1cbdb5aaf750cec11ea1
https://doi.org/10.1002/cpt.2757
https://doi.org/10.1002/cpt.2757
Publikováno v:
Folia Pharmacologica Japonica. 156:47-51
Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic window than conventional chemotherapeutic agents by substantiating efficient and specific drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb8a7438450ede43673503e32fe4bad6
https://doi.org/10.1254/fpj.20076
https://doi.org/10.1254/fpj.20076
Autor:
Kunika Kikumori, Tetsu Shinkai, Shunji Takahashi, Akihiko Shimomura, Takahiro Kamio, Ryo Nakamura, Eriko Tokunaga, Toshimi Takano, Junichiro Watanabe, Yasuaki Sagara, Toshinari Yamashita, Emi Kamiyama
Publikováno v:
Cancer Research. 80:P1-18
Background [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is a novel antibody-drug conjugate with a humanized anti-HER2 antibody, peptide-based cleavable linker, and topoisomerase I inhibitor payload (MAAA-1181a). T-DXd has a drug-to-antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4792a68b147c5c99c2b4b4bb752ca6c6
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-12
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-12
Autor:
Akihiko, Shimomura, Toshimi, Takano, Shunji, Takahashi, Yasuaki, Sagara, Junichiro, Watanabe, Eriko, Tokunaga, Tetsu, Shinkai, Takahiro, Kamio, Kunika, Kikumori, Emi, Kamiyama, Yoshihiko, Fujisaki, Dan, Saotome, Toshinari, Yamashita
Publikováno v:
Clinical pharmacology and therapeutics.
HER2-targeted anticancer therapies may be associated with cardiovascular adverse events. This study evaluated effects of the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd, DS-8201a) on QT/QTc interval and its pharmacokinetics. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a042b1746966a3986c0661c306618161
https://pubmed.ncbi.nlm.nih.gov/36164935
https://pubmed.ncbi.nlm.nih.gov/36164935
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 156(1)
Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic window than conventional chemotherapeutic agents by substantiating efficient and specific drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b704450798c26a76f6df12b41e5c922a
https://pubmed.ncbi.nlm.nih.gov/33390481
https://pubmed.ncbi.nlm.nih.gov/33390481
Autor:
Shoichi Ohwada, Kimio Yonesaka, Hironori Yamada, Hidetoshi Hayashi, Tsutomu Iwasa, Toshio Shimizu, Emi Kamiyama, Kazuhiko Nakagawa, Koji Haratani
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae2c1761334b9fc54d8fdff29275740
https://doi.org/10.1007/s00280-016-3231-3
https://doi.org/10.1007/s00280-016-3231-3
Autor:
Ichiro Kinoshita, Caleb Lee, Emi Kamiyama, T. Fujiki, Issei Achiwa, Y-H. Im, Hironobu Minami, Y.-J. Bang, Yasuyuki Okuda, M. Karayama, Masato Takahashi, Noboru Yamamoto, C-C. Lin, Satoshi Takahashi, J. Watanabe
Publikováno v:
Annals of Oncology. 31:S68-S69
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64c12966c29c67808fb16a7cd5e82a5
https://doi.org/10.1016/j.annonc.2020.03.247
https://doi.org/10.1016/j.annonc.2020.03.247
Autor:
Victor Dishy, Takashi Taguchi, Akiko Watanabe, Vijay Vashi, Robert Bass, Jin Zhou, Kazuhito Shiosakai, Emi Kamiyama, Hidetoshi Furuie, Yusuke Myobatake, Hitoshi Ishizuka, Manabu Kato, Vance Warren, Yutaro Maekawa
Publikováno v:
Clinical drug investigation. 39(10)
Non-clinical study data suggest that DS-8500a, a G protein-coupled receptor 119 agonist, exhibits antidiabetic activity, inhibition of some transporters and induction of cytochrome P450 (CYP) 3A. Statins are substrates for some transporters and CYP3A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de0aede4e781b834bc3da5b615ba654f
https://pubmed.ncbi.nlm.nih.gov/31321631
https://pubmed.ncbi.nlm.nih.gov/31321631
Autor:
Takafumi Yoshida, Takashi Taguchi, Emi Kamiyama, Hitoshi Ishizuka, Manabu Kato, Kazuhito Shiosakai, Michio Sata
Publikováno v:
Advances in therapy. 35(8)
The pharmacokinetics, safety, and tolerability of DS-8500a (a G protein receptor 119 agonist) up to 100 mg have been investigated in healthy Japanese adults. The objective of this study was to evaluate the effects of hepatic or renal impairment on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9d97d22bbd06a79b9ccfc0779b1d6b
https://pubmed.ncbi.nlm.nih.gov/29968010
https://pubmed.ncbi.nlm.nih.gov/29968010